Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

• DOI: 10.5326/jaaha-ms-5525
• Publication Date: 2011-04-16T07:30:13Z
• Authors: Nikolaos G. Dervisis; Pedro A. Dominguez; Rebecca G. Newman; Casey D. Cadile; Barbara E. Kitchell
• Keywords: Dacarbazine

Hemangiosarcoma (HSA) is an aggressive disease that fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol dogs with nonresectable stage II III HSA. Twenty-four were enrolled this prospective, phase 2 study. Doxorubicin dacarbazine administered on day 1 while was days 8 15. repeated every 21 for maximum of six cycles or until progression. Toxicity efficacy assessed by clinical laboratory evaluation questionnaires completed owners. Of 24 included dogs, 19 evaluable response. response rate (including five complete responses four partial responses) 47.4%. Median time to tumor progression 101 median overall survival 125 days. Significant toxicities noted, including 41 high-grade hematologic 12 gastrointestinal toxic events. Five discontinued treatment due chemotherapy-related toxicities, but no treatment-related deaths occurred. Multivariate analysis identified patient age (relative risk [RR], 2.3, P=0.049) be negatively associated whereas dose reductions (RR, 0.06, P=0.031) positively Dacarbazine reduction sole factor 0.28, P=0.015). In conclusion, DAV appears offer may prolong advanced-stage